Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Johnson & Johnson said it will invest more than $1 billion to build a new cell therapy manufacturing facility in Montgomery County, Pennsylvania. The project is part of a broader U.S. manufacturing expansion announced earlier, which includes plans to invest over $55 billion through early 2029. The company expects the Pennsylvania site to generate o…
U.S. factory production rebounded in January, rising 0.6% — the largest monthly gain since February 2025 — with gains recorded across durable and nondurable goods. Overall industrial output increased 0.7% as utilities and manufacturing led the advance, while mining declined. Capacity utilization and the manufacturing operating rate both inched high…
Stifel reduced its 12-month price target on Beta Bionics, Inc. (BBNX) to $22 from $25 while maintaining a Buy rating. The move follows a review of fourth-quarter 2025 metrics, including gross margin and operating expenses, and a look at 2026 guidance and regulatory updates. Beta Bionics reported a 59.0% Q4 2025 gross margin, revenue of $100.25 mill…
BofA Securities has begun coverage of Burford Capital with a buy rating and a price objective of $14.55 per share for the New York-listed stock and 1,062 pence for the London-listed shares. The U.S. target implies roughly 48% upside from a quoted price of $9.82. BofA highlights the company's cash returns on tangible equity exceeding its cost of equ…
RBC Capital Markets has flagged several luxury names as well positioned for 2026, citing recent quarterly results, product innovations and management moves. EssilorLuxottica posted particularly strong Q4 2025 performance aided by its smartglasses partnership and subscription initiatives. Hermès delivered solid margins and reiterated long-term volum…
Guggenheim reiterated a Buy rating on Madison Square Garden Sports Corp. and lifted its price target following the company’s announcement that its board will explore a tax-free spin-off of the New York Knicks and New York Rangers. The stock has jumped sharply in recent months and third-party franchise valuations imply substantial upside versus curr…
Cantor Fitzgerald cut its price target on Metaplanet (OTC: MTPLF) to $3.00 from $6.00 but maintained an Overweight rating. The update follows the company's Q4 and fiscal 2025 results, in which Bitcoin-related activity dominated revenue and the firm materially increased its Bitcoin holdings. InvestingPro data highlights valuation upside versus Fair …
Thomas D. Stoddard, a director at Prudential Financial, purchased 250 shares of the company’s common stock on February 17, 2026, for $102.97 per share, a transaction valued at $25,742. The purchase was made directly and leaves Stoddard owning 250 Prudential shares. Concurrent company developments include the adoption of 2026 incentive programs for …
Gold and silver both rose on Wednesday as markets balanced geopolitical developments with an eye toward the U.S. Federal Reserve's January meeting minutes due later in the day. Spot gold rebounded to just over $5,000 per ounce while silver jumped roughly 6% as investors assessed safe-haven demand, central bank purchases and ETF flows from Asia. A m…
Cantor Fitzgerald reaffirmed an Overweight rating and a $220 price objective for Palo Alto Networks (PANW) following the company’s latest quarterly report. Trading near $150.40, the stock sits roughly 35% below Cantor’s target. Palo Alto delivered results that beat FactSet consensus across several metrics, and management highlighted progress in AI …
Cantor Fitzgerald maintained an Overweight rating and a $111.00 price target on Goosehead Insurance Inc. (GSHD), highlighting an in-line quarterly result and a view that the stock could be rerated over time despite conservative guidance for 2026 and delayed margin expansion. Other brokerages issued mixed reactions following the quarter, with some l…
PPG Industries' Senior VP and CFO Vincent J. Morales sold 78,095 shares on February 13, 2026, for roughly $10.2 million and exercised options to acquire 49,656 shares the same day. The company reported fourth-quarter 2025 adjusted EPS of $1.51, below expectations of $1.58, while revenue of $3.91 billion exceeded the $3.78 billion forecast. Wolfe Re…
IREN is sitting at a crossroads: the stock is volatile after a weak quarter, but the company has secured financing, a confirmed large hyperscaler contract, and accelerating GPU capacity that should transform revenue mix from crypto to recurring AI cloud sales. This trade targets a re-rate as ARR ramps and institutional demand increases around index…
Leadership clarity at Disney is a meaningful positive, but the company’s turnaround — streaming profitability, park strength, potential asset moves — takes time. This trade idea sets a clear entry at $107.59 with a $130 target and a $95 stop, framed as a position trade that expects catalysts and execution to unfold over several months.
The Democratic Republic of Congo has added the Rubaya coltan mine, a major source of tantalum, to a shortlist of strategic assets it is offering to the United States under a bilateral minerals cooperation framework. A government document and confirmations from officials show Rubaya was presented to U.S. counterparts at a Washington meeting on Febru…
Iranians held 40-day mourning ceremonies this week for people killed during late-January unrest, renewing confrontations with security forces in several cities. Authorities moved to steer commemorations into state-run events and restricted communications, but independent memorials in cemeteries and communities became focal points for wider anti-gov…
Cantor Fitzgerald has reiterated an Overweight rating on Ideaya Biosciences (IDYA) as the company approaches a pivotal Phase 2/3 topline progression-free survival readout for darovasertib in late March. The trial, OptimUM-02, compares darovasertib plus crizotinib against physician-chosen regimens in first-line metastatic uveal melanoma. Investor fo…
D.A. Davidson reiterated a Neutral rating on Franklin Electric (FELE) and set a $90 price target after the company's fourth-quarter 2025 results. Sales and operating profit fell short of the firm's model, driven by volume weakness in Water Systems across several regions. Energy and Distribution segments delivered offsetting organic growth, while in…
Kevin Hassett, director of the White House National Economic Council and a senior economic adviser to President Donald Trump, sharply criticized a New York Federal Reserve research paper that concluded Americans primarily bear the costs of tariffs. Hassett called the study an "embarrassment," labeled it the "worst paper" he had seen in the Fed's hi…
Smith & Wesson (SWBI) has finished its relocation and is generating positive free cash flow again. At a market cap near $527M and free cash flow of $21.3M, the stock looks reasonably supported despite a high P/E. This trade idea targets $15.50 over a 180-trading-day horizon with a tight structural stop at $10.80 to limit downside if margins deterio…
Barclays analyst Venu Krishna says a recent market rotation has revealed fragility in the risk-on environment, prompting the bank to alter its factor views across U.S. and European equities. The bank highlights Value and Yield as beneficiaries of the rotation while Momentum weakens and defensive exposure re-emerges in Europe. In the U.S., Barclays …
Williams Trading downgraded Crocs to Sell from Hold, pointing to ongoing weakness in U.S. demand for both the Crocs brand and HEYDUDE and expressing concern that expanding company-owned stores may not revive growth. The firm raised its price target to $84 from $75 and increased estimates for accounting reasons, but said fundamentals remain soft and…
DA Davidson cut its price objective on Vulcan Materials Company to $320 from $330 while keeping a Neutral rating, following a fourth quarter that underperformed expectations. The firm trimmed its 2026 estimates amid slower pricing and volume trends and flagged housing-market headwinds and a transition year in the federal highway bill. Vulcan report…
ImmunityBio stock rose sharply after the European Commission granted conditional marketing authorization for ANKTIVA in combination with BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The approval covers the 27 EU member states plus Iceland, Norway and Liechtenstein, bringing ANKTIVA’s regulatory reach to 3…
DA Davidson lowered its price target on Palo Alto Networks to $190 from $210 while keeping a Buy rating after the company’s fiscal second-quarter results. The analyst flagged underwhelming organic next‑generation security annual recurring revenue (ARR) and remaining performance obligations (RPO) upside versus investor expectations, even as several …
